


UNITED STATES PATENT AND TRADEMARK OFFICE

Re: Application of: Ronald M. BURCH, *et al.*
Serial No.: Not yet assigned
Filed: Herewith
For: **ANALGESIC COMBINATION OF OXYCODONE
AND MELOXICAM**



INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents and Trademarks
Washington, D.C. 20231

January 25, 2002

Sir:

In accordance with the provisions of 37 C.F.R. § 1.97, Applicants hereby make of record the documents listed on the accompanying PTO-1449 Form for consideration by the Examiner in connection with the examination of the above-noted patent application.

In accordance with 37 C.F.R. § 1.98(d), copies of the listed references are not enclosed as the references cited in the attached Form PTO-1449 have been previously submitted to the PTO or were cited by the Examiner during prosecution of parent application, U.S. Serial No. 09/154,354, entitled, "Analgesic Combination Of Oxycodone And Rofecoxib."

The Examiner's attention is directed to the following copending related applications:

U.S. Serial No. (Not yet known), filed, December 27, 2001, entitled "Analgesic Combination of Oxycodone and Celecoxib",

U.S. Serial No. (Not yet known), filed, January 25, 2002, entitled "Analgesic Combination of Oxycodone and 6-MNA",

U.S. Serial No. (Not yet known), filed, January 25, 2002, entitled "Analgesic Combination of Oxycodone and Nabumetone",

U.S. Serial No. (Not yet known), filed, January 25, 2002, entitled "Analgesic Combination of Oxycodone and Nimesulide",

U.S. Serial No. (Not yet known), filed, January 25, 2002, entitled "Analgesic Combination of Oxycodone and SC-58215" and


U.S. Serial No. (Not yet known), filed, January 25, 2002, entitled "Analgesic Combination of Oxycodone and T-614".

It is respectfully requested that the references cited in the accompanying PTO-1449 Form be considered and made of record. If any of the publications listed thereon are missing, the Examiner is requested to contact the undersigned so that a copy can be promptly forwarded.

This information disclosure statement is being filed together with the filing of the application and before the mailing date of a first Office Action on the merits. Therefore, under 37 C.F.R. § 1.97 (b), it is believed no fee is required. If it is determined that any fees are due at this time, the Assistant Commissioner is hereby authorized to charge said fees to Deposit Account No. 50-0552.

Respectfully submitted,
DAVIDSON, DAVIDSON & KAPPEL, LLC

By


Robert J. Paradiso
Reg. No. 41,240

Davidson, Davidson & Kappel, LLC
485 Seventh Avenue, 14th Floor
New York, New York 10018
(212) 736-1940